Mendelian randomization identifies blood metabolites previously linked to midlife cognition as causal candidates in Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Significance: The absence of disease-modifying therapeutics for Alzheimer’s disease (AD) continues, and an understanding of early, easily accessible biomarkers to inform treatment strategies remains elusive. This study uses knowledge of blood metabolites previously associated with midlife cognition—a preclinical predictor of AD—to systematically investigate causal associations with later AD status. Given that the pathological changes underlying AD are thought to develop years before clinical manifestations of the disease, developing these findings further could hold special utility in informing early treatment intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bowden, J., Davey Smith, G., & Burgess, S. (2015) · International Journal of Epidemiology · doi:10.1093/ije/dyv080 · Cited by 9,816 · cited 1×
“Large deviations from zero are taken as evidence of violation to MR’s exclusion restriction and exchangeability assumptions (45), and large discrepancies between Egger and IVW estimates are”
Bowden, J., Davey Smith, G., Haycock, P. C., & Burgess, S. (2016) · Genetic Epidemiology · doi:10.1002/gepi.21965 · Cited by 8,922 · cited 1×
“Weighted median provided an alternative estimate which remains valid provided 50% of instruments are valid (46).”
Verbanck, M., Chen, C.-Y., Neale, B., & Do, R. (2018) · Nature Genetics · doi:10.1038/s41588-018-0099-7 · Cited by 8,591
The MR-Base platform supports systematic causal inference across the human phenome
Hemani, G., Zheng, J., Elsworth, B., Wade, K. H., Haberland, V., Baird, D., Laurin, C., Burgess, S., Bowden, J., Langdon, R., et al. (2018) · eLife · doi:10.7554/elife.34408 · Cited by 7,959
An atlas of genetic correlations across human diseases and traits
ReproGen Consortium, Bulik-Sullivan, B., Psychiatric Genomics Consortium, Genetic Consortium for Anorexia Nervosa of the Wellcome Trust Case Control Consortium 3, Finucane, H. K., Anttila, V., Gusev, A., Day, F. R., Loh, P.-R., Duncan, L., et al. (2015) · Nature Genetics · doi:10.1038/ng.3406 · Cited by 4,255
Burgess, S., & Thompson, S. G. (2015) · American Journal of Epidemiology · doi:10.1093/aje/kwu283 · Cited by 1,605
Guidelines for performing Mendelian randomization investigations
Burgess, S., Davey Smith, G., Davies, N. M., Dudbridge, F., Gill, D., Glymour, M. M., Hartwig, F. P., Holmes, M. V., Minelli, C., Relton, C. L., et al. (2020) · Wellcome Open Research · doi:10.12688/wellcomeopenres.15555.2 · Cited by 1,273 · cited 2×
“SNPs associated with AD at GWS were excluded due to potential violation of the MR exchangeability assumption (39), which assumes SNP instruments are not associated with confounding risk factors.”
Neuropsychiatric symptoms in Alzheimer's disease
Lyketsos, C. G., Carrillo, M. C., Ryan, J. M., Khachaturian, A. S., Trzepacz, P., Amatniek, J., Cedarbaum, J., Brashear, R., & Miller, D. S. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.05.2410 · Cited by 1,139 · cited 1×
“The most common dementia type is Alzheimer’s disease (AD), characterized by impaired everyday function, severe cognitive decline—particularly working, episodic, and declarative memory (1)—and a range of neuropsychiatric symptoms (2).”
Apolipoprotein E: Structure and function in lipid metabolism, neurobiology, and Alzheimer’s diseases
Huang, Y., & Mahley, R. W. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.08.025 · Cited by 829
Kettunen, J., Demirkan, A., Würtz, P., Draisma, H. H. M., Haller, T., Rawal, R., Vaarhorst, A., Kangas, A. J., Lyytikäinen, L.-P., Pirinen, M., et al. (2016) · Nature Communications · doi:10.1038/ncomms11122 · Cited by 738
Memory loss in Alzheimer's disease
Jahn, H. (2013) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2013.15.4/hjahn · Cited by 653 · cited 1×
“The most common dementia type is Alzheimer’s disease (AD), characterized by impaired everyday function, severe cognitive decline—particularly working, episodic, and declarative memory (1)—and a range of neuropsychiatric symptoms (2).”
Deelen, J., Kettunen, J., Fischer, K., van der Spek, A., Trompet, S., Kastenmüller, G., Boyd, A., Zierer, J., van den Akker, E. B., Ala-Korpela, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11311-9 · Cited by 362 · cited 1×
“Additionally, alpha-1-acid glycoprotein has been shown to be a strong predictor of 10 y mortality (34) as well as all-cause mortality in a recent large meta-analysis of >40K individuals (35).”
Fischer, K., Kettunen, J., Würtz, P., Haller, T., Havulinna, A. S., Kangas, A. J., Soininen, P., Esko, T., Tammesoo, M.-L., Mägi, R., et al. (2014) · PLoS Medicine · doi:10.1371/journal.pmed.1001606 · Cited by 344 · cited 1×
“Additionally, alpha-1-acid glycoprotein has been shown to be a strong predictor of 10 y mortality (34) as well as all-cause mortality in a recent large meta-analysis of >40K individuals (35).”
HDL-Cholesterol, Total Cholesterol, and the Risk of Stroke in Middle-Aged British Men
Wannamethee, S. G., Shaper, A. G., & Ebrahim, S. (2000) · Stroke · doi:10.1161/01.str.31.8.1882 · Cited by 220 · cited 1×
“Within the medical literature, higher levels of HDLs are commonly referred to as being health promoting, demonstrating vascular protective properties and a consistent association with lowered cardiovascular and stroke risk (25 – 29).”
Østergaard, S. D., Mukherjee, S., Sharp, S. J., Proitsi, P., Lotta, L. A., Day, F., Perry, J. R. B., Boehme, K. L., Walter, S., Kauwe, J. S., et al. (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001841 · Cited by 203
Self-citationCirculating metabolites and general cognitive ability and dementia: evidence from 11 cohort studies
van der Lee, S. J., Teunissen, C. E., Pool, R., Shipley, M. J., Teumer, A., Chouraki, V., Melo van Lent, D., Tynkkynen, J., Fischer, K., Hernesniemi, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.11.012 · Cited by 197 · cited 2×
“This risk-increasing relationship aligns with our previous study (16), which observed an association between GP and lower cognitive ability in late midlife, consistent with findings from a large independent cohort (14).”
HDL from an Alzheimer's disease perspective
Button, E. B., Robert, J., Caffrey, T. M., Fan, J., Zhao, W., & Wellington, C. L. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000604 · Cited by 114 · cited 2×
“Results are also supported by existing AD GWAS, with SNP associations found near genes encoding HDL protein components and biogenesis proteins such as APOE , ABCA1 , APOA1 and 2 , CLU , LCAT , and CETPI (31).”
Kunkle, B., Grenier-Boley, B., Sims, R., Bis, J., Naj, A., Boland, A., Vronskaya, M., van der Lee, S., Amlie-Wolf, A., Bellenguez, C., et al. (2018) · doi:10.1101/294629 · Cited by 35
Self-citation
Cited by
Small molecule metabolites: discovery of biomarkers and therapeutic targets
Qiu, S., Cai, Y., Yao, H., Lin, C., Xie, Y., Tang, S., & Zhang, A. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01399-3 · Cited by 884
Liu, H., Hu, Y., Zhang, Y., Zhang, H., Gao, S., Wang, L., Wang, T., Han, Z., Sun, B.-L., & Liu, G. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-00963-3 · Cited by 51
Zheng, S., Liu, L., Liang, K., Yan, J., Meng, D., Liu, Z., Tian, S., & Shan, Y. (2024) · Communications Biology · doi:10.1038/s42003-024-06680-x · Cited by 15
Wu, Y., Chen, F., Zhang, T., Miao, M., Zhang, M., Zhang, J., & Chang, E. (2025) · Metabolomics · doi:10.1007/s11306-025-02242-2 · Cited by 2
“…2023a; Luo et al., 2023; Qiang Zhang et al., 2020; Tan et al., 2022 ), five stud - ies associated with HDL-C (Huang et al., 2021a; Li et al., 2023a; Lord et al., 2021; Luo et al., 2023; Qiang Zhang et al., 2020), three studies related to glutamine (Adams et al., Therefore, we use the value of the…”
Metadata
- Authors
- Lord, J., Jermy, B., Green, R., Wong, A., Xu, J., Legido-Quigley, C., Dobson, R., Richards, M., & Proitsi, P.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2021-04-16
- Volume
- 118
- Issue
- 16
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W3154089519
- Cited by
- 63
- References
- 18
- FWCI
- 7.46
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.